Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
Rhea-AI Summary
Interpace Biosciences (OTCQX: IDXG) reported third quarter 2025 results for the period ended September 30, 2025. Net revenue was $8.8 million; cash collections were $10.0 million. The company said thyroid test volume rose 12% year‑over‑year and thyroid revenue reached a record $8.8M, up 22% versus a prior pro forma quarter, while average revenue per test increased 5%. Management reported income from continuing operations of $1.0 million and adjusted EBITDA of $1.3 million. The company noted a 22% reduction in days sales outstanding and additional principal payments on long‑term debt tied to stronger cash flow.
Positive
- Thyroid test volume +12% year-over-year to record levels
- Thyroid revenue +22% to $8.8M (record)
- Average revenue per test +5%
- Cash collections $10.0M supporting operations and debt paydown
- Adjusted EBITDA $1.3M and income from continuing operations $1.0M
Negative
- Total revenue down 29% versus prior year quarter to $8.8M
- Operating income fell from $2.3M to $1.1M year-over-year
- Cash collections declined ~11% from $11.2M in prior year quarter
- Gross profit margin slipped to 62% from 64% year-over-year
News Market Reaction 1 Alert
On the day this news was published, IDXG declined 3.00%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
| ● | Q3 Revenue of | |
| ● | Q3 Cash Collections of | |
| ● | Q3 Thyroid test volume up | |
| ● | Q3 Thyroid revenue of | |
PARSIPPANY, NJ, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2025 and provided a business and financial update.
Third quarter Net Revenue was
“The third quarter represented the first full quarter of the Company being a Thyroid-only diagnostics testing company”, said Tom Burnell, President and CEO. “We are excited about the Company’s continued growth in revenue, profitability and cash flow as a Thyroid- only clinical diagnostics business”, added Burnell. Further, Burnell said, “We believe our unique combination testing platform delivers the confidence of high performance with the convenience of simple specimen handling. ThyGeNEXT® evaluates the most common mutations in thyroid cancer, while the microRNA signatures assessed by ThyraMIR®v2 provide insights across both major and minor cancer-related signaling pathways. This comprehensive ‘panel-to-pathways’ approach supports physicians in making confident and informed patient-management decisions.”
Third Quarter 2025 Financial Performance
For the Third Quarter of 2025 as Compared to the Third Quarter of 2024 and Pro Forma 2024 Results1
| ● | Revenue was | |
| ● | Gross Profit percentage was | |
| ● | Operating income was | |
| ● | Income from continuing operations was | |
| ● | Adjusted EBITDA was | |
| ● | Q3 2025 cash collections totaled | |
About Interpace Biosciences
Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has two commercialized molecular tests: ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and ThyraMIRv2, used in combination with ThyGeNEXT, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification.
For more information, please visit Interpace Biosciences’ website at www.interpace.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the possibility that the Company’s estimates of future revenue and cash flows, as well as Pro Forma financial results and adjusted EBITDA may prove to be materially inaccurate, the Company’s prior history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s ability to repay borrowings from BroadOak, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect, and the Company’s ability to continue to restructure itself in light of the loss of reimbursement for its PancraGEN product.
Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as amended, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts:
Investor Relations
Interpace Biosciences, Inc.
(855)-776-6419
Info@Interpace.com
INTERPACE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share data)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue, net | $ | 8,756 | $ | 12,295 | $ | 29,504 | $ | 34,515 | ||||||||
| Cost of revenue | 3,317 | 4,393 | 11,418 | 12,496 | ||||||||||||
| Gross Profit | 5,439 | 7,902 | 18,086 | 22,019 | ||||||||||||
| Sales and marketing | 2,087 | 2,864 | 7,811 | 8,571 | ||||||||||||
| Research and development | 150 | 199 | 500 | 483 | ||||||||||||
| General and administrative | 2,057 | 2,538 | 7,268 | 6,918 | ||||||||||||
| Total operating expenses | 4,294 | 5,601 | 15,579 | 15,972 | ||||||||||||
| Operating income | 1,145 | 2,301 | 2,507 | 6,047 | ||||||||||||
| Interest accretion expense | - | (4 | ) | - | (34 | ) | ||||||||||
| Note payable interest | (30 | ) | (141 | ) | (156 | ) | (514 | ) | ||||||||
| Other expense, net | (115 | ) | (394 | ) | (112 | ) | (406 | ) | ||||||||
| Income from continuing operations before tax | 1,000 | 1,762 | 2,239 | 5,093 | ||||||||||||
| (Benefit) provision for income taxes | (11 | ) | 4 | 7 | 12 | |||||||||||
| Income from continuing operations | 1,011 | 1,758 | 2,232 | 5,081 | ||||||||||||
| Loss from discontinued operations, net of tax | (100 | ) | (82 | ) | (314 | ) | (260 | ) | ||||||||
| Net income | $ | 911 | $ | 1,676 | $ | 1,918 | $ | 4,821 | ||||||||
| Basic income (loss) per share of common stock: | ||||||||||||||||
| From continuing operations | $ | 0.23 | $ | 0.40 | $ | 0.50 | $ | 1.16 | ||||||||
| From discontinued operations | (0.02 | ) | (0.02 | ) | (0.07 | ) | (0.06 | ) | ||||||||
| Net income (loss) per basic share of common stock | $ | 0.21 | $ | 0.38 | $ | 0.43 | $ | 1.10 | ||||||||
| Diluted income (loss) per share of common stock: | ||||||||||||||||
| From continuing operations | $ | 0.04 | $ | 0.40 | $ | 0.08 | $ | 1.15 | ||||||||
| From discontinued operations | (0.01 | ) | (0.02 | ) | (0.01 | ) | (0.06 | ) | ||||||||
| Net income (loss) per diluted share of common stock | $ | 0.03 | $ | 0.38 | $ | 0.07 | $ | 1.09 | ||||||||
| Weighted average number of common shares and | ||||||||||||||||
| common share equivalents outstanding: | ||||||||||||||||
| Basic | 4,425 | 4,393 | 4,423 | 4,380 | ||||||||||||
| Diluted | 27,695 | 4,423 | 27,693 | 4,404 | ||||||||||||
Selected Balance Sheet Data (Unaudited)
($ in thousands)
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Cash and cash equivalents | $ | 1,423 | $ | 1,461 | ||||
| Total current assets | 9,130 | 11,773 | ||||||
| Total current liabilities | 5,945 | 10,615 | ||||||
| Total assets | 12,036 | 14,792 | ||||||
| Total liabilities | 12,334 | 17,009 | ||||||
| Total stockholders' deficit | (298 | ) | (2,217 | ) | ||||
Selected Cash Flow Data (Unaudited)
($ in thousands)
| For the Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2025 | 2024 | |||||||
| Net income | $ | 1,918 | $ | 4,821 | ||||
| Net cash provided by operating activities | $ | 3,693 | $ | 3,462 | ||||
| Net cash used in investing activities | (318 | ) | (747 | ) | ||||
| Net cash used in financing activities | (3,413 | ) | (4,100 | ) | ||||
| Change in cash and cash equivalents | (38 | ) | (1,385 | ) | ||||
| Cash and cash equivalents – beginning | 1,461 | 3,498 | ||||||
| Cash and cash equivalents – ending | $ | 1,423 | $ | 2,113 | ||||
| Reconciliation of Pro Forma (Unaudited) | ||||||||||||
| (in thousands, except per share data) | ||||||||||||
| Three Months Ended September 30, 2024 | ||||||||||||
| PancraGEN | ||||||||||||
| As Reported | Direct Costs* | Pro Forma | ||||||||||
| Revenue, net | $ | 12,295 | $ | 5,040 | $ | 7,255 | ||||||
| Cost of revenue | 4,393 | 1,242 | 3,151 | |||||||||
| Gross Profit | 7,902 | 3,798 | 4,104 | |||||||||
| Sales and marketing | 2,864 | 1,146 | 1,718 | |||||||||
| Research and development | 199 | 79 | 120 | |||||||||
| General and administrative | 2,538 | 152 | 2,386 | |||||||||
| Total operating expenses | 5,601 | 1,377 | 4,224 | |||||||||
| Operating income (loss) | 2,301 | 2,421 | (120 | ) | ||||||||
| Interest accretion expense | (4 | ) | - | (4 | ) | |||||||
| Note payable interest | (141 | ) | - | (141 | ) | |||||||
| Other expense, net | (394 | ) | - | (394 | ) | |||||||
| Income (loss) from continuing operations before tax | 1,762 | 2,421 | (659 | ) | ||||||||
| Provision for income taxes | 4 | - | 4 | |||||||||
| Income (loss) from continuing operations | 1,758 | 2,421 | (663 | ) | ||||||||
| Loss from discontinued operations, net of tax | (82 | ) | - | (82 | ) | |||||||
| Net income (loss) | $ | 1,676 | $ | 2,421 | $ | (745 | ) | |||||
| Basic income (loss) per share of common stock: | ||||||||||||
| From continuing operations | $ | 0.40 | $ | 0.55 | $ | (0.15 | ) | |||||
| From discontinued operations | (0.02 | ) | - | (0.02 | ) | |||||||
| Net income (loss) per basic share of common stock | $ | 0.38 | $ | 0.55 | $ | (0.17 | ) | |||||
| Diluted income (loss) per share of common stock: | ||||||||||||
| From continuing operations | $ | 0.40 | $ | 0.55 | $ | (0.15 | ) | |||||
| From discontinued operations | (0.02 | ) | - | (0.02 | ) | |||||||
| Net income (loss) per diluted share of common stock | $ | 0.38 | $ | 0.55 | $ | (0.17 | ) | |||||
| Weighted average number of common shares and | ||||||||||||
| common share equivalents outstanding: | ||||||||||||
| Basic | 4,393 | 4,393 | 4,393 | |||||||||
| Diluted | 4,423 | 4,423 | 4,423 | |||||||||
* PancraGEN Direct Costs represent only direct costs associated with the operations of PancraGEN testing, with no allocations or estimates of corporate, shared, or overhead expenses included.
Reconciliation of Adjusted EBITDA (Unaudited)
($ in thousands)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Income from continuing operations (GAAP Basis) | $ | 1,011 | $ | 1,758 | $ | 2,232 | $ | 5,081 | ||||||||
| Depreciation and amortization | 111 | 85 | 307 | 205 | ||||||||||||
| Stock-based compensation | 7 | 86 | 31 | 218 | ||||||||||||
| Severance & related expense | - | - | 692 | - | ||||||||||||
| Asset impairment - lab supplies | - | - | 198 | - | ||||||||||||
| Taxes (benefit) expense | (11 | ) | 4 | 7 | 12 | |||||||||||
| Interest accretion expense | - | 4 | - | 34 | ||||||||||||
| Note payable interest | 30 | 141 | 156 | 514 | ||||||||||||
| Other expense/income, net | 10 | (10 | ) | 25 | (40 | ) | ||||||||||
| Change in fair value of note payable | 105 | 404 | 87 | 445 | ||||||||||||
| Adjusted EBITDA | $ | 1,263 | $ | 2,472 | $ | 3,735 | $ | 6,469 | ||||||||
Non-GAAP Financial Measures
In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.
In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock-based compensation, severance expense, interest and taxes, and other non-cash expenses including change in fair values of notes payable. The table above includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.
1 Management uses a non-GAAP Pro Forma income statement to help evaluate the results of our performance. The Pro Forma income statement for 2024 reflects the Company’s current business structure as a thyroid-only diagnostics testing company and excludes revenue and related costs from PancraGEN, which was discontinued in May 2025. These adjustments are presented for comparability purposes only and do not represent GAAP financial measures. Investors should review GAAP results alongside these pro forma figures for a complete understanding of performance. A reconciliation of GAAP and these pro forma figures is presented below.
FAQ
What were Interpace Biosciences (IDXG) Q3 2025 revenue and cash collections?
How did Interpace's thyroid testing perform in Q3 2025 (IDXG)?
What profitability metrics did Interpace (IDXG) report for Q3 2025?
Did Interpace (IDXG) report any improvements in receivables or collections in Q3 2025?
How did Q3 2025 results compare to Q3 2024 for Interpace (IDXG)?
